“…Although no conclusive association has been found thus far, there are several indications that polymorphisms could contribute to the pathogenesis of the disorder or to the response to pharmacological treatments. For example, variants in the D2, D3, and D4 dopamine receptor genes have been linked to schizophrenia or to the response to antipsychotic treatments (Parsons et al, 2007;Bertram, 2008;Rondou et al, 2010), DRD4 and DRD5 have been consistently linked to candidate genes for ADHD (Coghill and Banaschewski, 2009;Gizer et al, 2009), and the D2 dopamine receptor gene has been associated with substance abuse (Le Foll et al, 2009), prolactin-secreting pituitary adenomas (Filopanti et al, 2010), and several other conditions. However, as noted by Wong et al (2000), "while there is some evidence that polymorphisms and mutations in dopamine receptors can alter functional activity and pharmacological profiles, no conclusive data link these gene variants to drug response or disease."…”